Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Código QR

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Pijian Yang1,*, Yuzhen Liang2,*, Yunchen Luo,2 Zhengming Li,2 Yumei Wen,1 Jing Shen,1 Ruwen Li,1 Hua Zheng,3 Harvest F Gu4,*, Ning Xia1,*1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; 2De...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Glucagon like peptide 1 Liraglutide Nonalcoholic fatty liver disease Insulin resistance Insulin signaling Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/46cd31beb13d45f5b0ecb6789895100c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?
por: Ekaterina E. Mishina, et al.
Publicado: (2017)

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
por: Igor A. Sklyanik, et al.
Publicado: (2021)

Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway
por: Liu H, et al.
Publicado: (2020)

To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
por: Yin J, et al.
Publicado: (2021)

Association of insulin resistance and non-alcoholic fatty liver disease
por: Ekaterina E. Mishina, et al.
Publicado: (2021)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
por: Lyudmila Alexandrovna Ruyatkina, et al.
Publicado: (2017)

EXPRESSION OF TLR2, TLR3, TLR4 AND PROINFLAMMATORY TNF AND IL-6 CYTOKINES IN LIVER BIOPSIES OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS
por: A. V. Bogolyubova, et al.
Publicado: (2019)

The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016)

Electromagnetic Fields Ameliorate Insulin Resistance and Hepatic Steatosis by Modulating Redox Homeostasis and SREBP-1c Expression in db/db Mice
por: Zhai M, et al.
Publicado: (2021)

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
por: Filip R, et al.
Publicado: (2018)

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
por: Apollinariya V. Bogolyubova, et al.
Publicado: (2017)

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
por: Li C, et al.
Publicado: (2021)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee J, et al.
Publicado: (2019)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng F, et al.
Publicado: (2019)

Identification of key genes and pathways in mild and severe nonalcoholic fatty liver disease by integrative analysis
por: Jin Feng, et al.
Publicado: (2021)

Effects of duodenal–jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats
por: Yu HH, et al.
Publicado: (2019)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
por: Alexander Sergeevich Ametov
Publicado: (2015)

Role of oxidative stress and glutathione system in the pathogenesis of nonalcoholic fatty liver disease
por: T. E. Promenasheva, et al.
Publicado: (2014)

Analysis of prevalence of risk factor of nonalcoholic fatty liver disease in the Buryat Republic
por: E. G. Naydanova
Publicado: (2015)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch D, et al.
Publicado: (2018)

Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta‐analysis
por: Shahinul Alam, et al.
Publicado: (2021)

Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease
por: Fan Y, et al.
Publicado: (2021)

Detection of Secondary Metabolites as Biomarkers for the Early Diagnosis and Prevention of Type 2 Diabetes
por: Al-Aama JY, et al.
Publicado: (2019)

Effects of exogenous α-(1,4)-amylase on the utilisation of corn starch and glucose metabolism in broiler chickens
por: H. Zhou, et al.
Publicado: (2021)

Mutations Affecting Mammalian Aging: GH and GHR vs IGF-1 and Insulin
por: Andrzej Bartke, et al.
Publicado: (2021)

Therapeutic Targeting of Nonalcoholic Fatty Liver Disease by Downregulating SREBP-1C Expression via AMPK-KLF10 Axis
por: Yu-Chi Chen, et al.
Publicado: (2021)

PARTICIPATION OF APOLIPOPROTEIN E IN TRANSFER AND ABSORPTION OF FATTY ACIDS BY THE CELLS And CAUSING OF HYPERLIPOPROTEINEMIA
por: V. N. Titov, et al.
Publicado: (2014)

Palmatine ameliorates high fat diet induced impaired glucose tolerance
por: Tian,Xusheng, et al.
Publicado: (2020)

Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology
por: Guo Q, et al.
Publicado: (2021)

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
por: Jelena Vekic, et al.
Publicado: (2021)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch D, et al.
Publicado: (2021)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao YQ, et al.
Publicado: (2016)

Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD
por: Klaudia Sztolsztener, et al.
Publicado: (2021)

Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease
por: Na Fei, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease (NAFLD) – a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients
por: Mikolasevic I, et al.
Publicado: (2014)

Insulin signaling proteins in pancreatic islets of insulin-resistant rats induced by glucocorticoid
por: De Paula,Flávia MM, et al.
Publicado: (2011)